Developer of human gene-based therapies. The company has developed a platform to bring new disease-modifying therapies to patients with severe disorders. The company's pipeline includes gene-based therapies for lipoprotein lipase deficiency, or LPLD, Sanfilippo B, Parkinson's Disease and Hemophilia B. read more
uniQure CEO & Leadership Team Ratings
Matthew Kapusta and the uniQure leadership team are scored a B by 6 employees placing it in the Top 25% of companies sized 201-500 Employees. The Leadership score includes details about how employees evaluate their executive team, CEO and manager.
Based on 15 ratings, the Leadership score of 83/100 combines employee feedback on their CEO (75/100), Manager (84/100), and Executive Team (81/100).
Matthew Kapusta uniQure CEO Rating
Top 30% Compared to other companies of similar sizeB
75 / 100
Matthew Kapusta the CEO of uniQure received an average score of 75 from uniQure employees.uniQure Manager Rating
Top 15% Compared to other companies of similar sizeA-
84 / 100
uniQure Executive Team Rating
Top 20% Compared to other companies of similar sizeB+
81 / 100
×